La Jolla Pharmaceutical Company

NasdaqCM:LJPC Stock Report

Market Cap: US$155.1m

This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

La Jolla Pharmaceutical Management

Management criteria checks 3/4

La Jolla Pharmaceutical's CEO is Larry Edwards, appointed in Jul 2020, has a tenure of 2.08 years. total yearly compensation is $2.39M, comprised of 23% salary and 77% bonuses, including company stock and options. directly owns 0.048% of the company’s shares, worth $74.45K. The average tenure of the management team and the board of directors is 2.1 years and 7.7 years respectively.

Key information

Larry Edwards

Chief executive officer

US$2.4m

Total compensation

CEO salary percentage23.02%
CEO tenure2.1yrs
CEO ownership0.05%
Management average tenure2.1yrs
Board average tenure7.7yrs

Recent management updates

Analysis Article Jan 05

Should You Take Comfort From Insider Transactions At La Jolla Pharmaceutical Company (NASDAQ:LJPC)?

It is not uncommon to see companies perform well in the years after insiders buy shares. Unfortunately, there are also...

Recent updates

Seeking Alpha Jul 11

Innoviva to acquire La Jolla Pharma for $149M including debt

Innoviva, Inc. (INVA), a diversified holding company, has agreed to acquire the commercial-stage biotech La Jolla Pharmaceutical Company (NASDAQ:LJPC) for $6.23 per share in cash, implying an enterprise value of ~$149M, the companies announced on Monday. Per the terms of the merger agreement, Innoviva (INVA) intends to pay $5.95 per share for La Jolla (LJPC) and $0.28 per share for additional cash proceeds from the divestiture of a non-core asset. The initial purchase price of $5.95 indicates a premium of 70% to the 30-day volume-weighted average price (VWAP). Innoviva (INVA), through one of its subsidiaries, will start a tender offer in this regard on or before July 25, 2022. The deal is expected to close within 30 business days. In 2017, the FDA approved La Jolla’s (LJPC) lead product to increase blood pressure in adults with septic or other distributive shock. A year later, the agency greenlighted its second product XERAVA as a treatment for adults with complicated intra-abdominal infections. The company reported $43.5M of net product sales in 2021 with ~30% YoY growth.
Analysis Article Nov 11

We Think La Jolla Pharmaceutical's (NASDAQ:LJPC) Robust Earnings Are Conservative

The subdued stock price reaction suggests that La Jolla Pharmaceutical Company's ( NASDAQ:LJPC ) strong earnings didn't...
Seeking Alpha Jul 02

Our Take On La Jolla Pharmaceutical Company

La Jolla Pharmaceutical Company (LJPC) strengthened its balance sheet with upfront money from the EU commercial rights to its two septic shock related products. Although Giapreza sales have been uninspiring since its 2018 launch, the company is nearing cash flow positive, owing to the lack of a meaningful R&D effort since a 2019 restructuring. With a market cap less than two times forecasted 2022 sales and insider buying, La Jolla merited a deeper dive. A full investment analysis follows in the paragraphs below.
Analysis Article Mar 11

La Jolla Pharmaceutical's (NASDAQ:LJPC) Shareholders Are Down 82% On Their Shares

While it may not be enough for some shareholders, we think it is good to see the La Jolla Pharmaceutical Company...
Analysis Article Feb 11

Market Sentiment Around Loss-Making La Jolla Pharmaceutical Company (NASDAQ:LJPC)

We feel now is a pretty good time to analyse La Jolla Pharmaceutical Company's ( NASDAQ:LJPC ) business as it appears...
Analysis Article Jan 16

Industry Analysts Just Upgraded Their La Jolla Pharmaceutical Company (NASDAQ:LJPC) Revenue Forecasts By 18%

Celebrations may be in order for La Jolla Pharmaceutical Company ( NASDAQ:LJPC ) shareholders, with the analysts...
Analysis Article Jan 05

Should You Take Comfort From Insider Transactions At La Jolla Pharmaceutical Company (NASDAQ:LJPC)?

It is not uncommon to see companies perform well in the years after insiders buy shares. Unfortunately, there are also...
Analysis Article Dec 09

Could The La Jolla Pharmaceutical Company (NASDAQ:LJPC) Ownership Structure Tell Us Something Useful?

The big shareholder groups in La Jolla Pharmaceutical Company ( NASDAQ:LJPC ) have power over the company. Generally...

CEO Compensation Analysis

How has Larry Edwards's remuneration changed compared to La Jolla Pharmaceutical's earnings?
DateTotal CompensationSalaryCompany Earnings
Jun 30 2022n/an/a

US$4m

Mar 31 2022n/an/a

US$5m

Dec 31 2021US$2mUS$550k

US$20m

Sep 30 2021n/an/a

US$12m

Jun 30 2021n/an/a

US$3m

Mar 31 2021n/an/a

-US$16m

Dec 31 2020US$3mUS$208k

-US$39m

Compensation vs Market: Larry's total compensation ($USD2.39M) is above average for companies of similar size in the US market ($USD1.53M).

Compensation vs Earnings: Larry's compensation has been consistent with company performance over the past year.


CEO

Larry Edwards (50 yo)

2.1yrs
Tenure
US$2,389,409
Compensation

Mr. Larry G. Edwards has been President and Chief Executive Officer at La Jolla Pharmaceutical Company since July 2020. Mr. Edwards serves as Director at La Jolla Pharmaceutical Company since October 29, 2...


Leadership Team

NamePositionTenureCompensationOwnership
Larry Edwards
President2.1yrsUS$2.39m0.048%
$ 74.5k
Michael Hearne
CFO & Secretary2.2yrsUS$504.10k0.041%
$ 63.4k
Paula Rusu
Vice President of Operations1.8yrsno datano data
Sandra Vedrick
Senior Director of Investor Relations & Human Resourcesno datano datano data
Luke Seikkula
Senior Vice President of Pharmaceutical Operations3.5yrsno datano data
Lakhmir Chawla
Consultant7.1yrsUS$707.29kno data
Stewart Kroll
Chief Development Officer2.7yrsno datano data
Mark Williams
Senior Vice President of Medical Affairs1.9yrsno datano data
Tony Hodges
Chief Medical Officerless than a yearno datano data
2.1yrs
Average Tenure
58yo
Average Age

Experienced Management: LJPC's management team is considered experienced (2.1 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Larry Edwards
President1.8yrsUS$2.39m0.048%
$ 74.5k
Kevin Tang
Chairman of the Board8yrsUS$105.86k0.45%
$ 696.6k
David Ramsay
Independent Director2.8yrsUS$165.86k0.40%
$ 622.0k
Tomas Ganz
Member of Scientific Advisory Board8.5yrsno datano data
Laura Douglass
Independent Director8.8yrsUS$165.86k0.0020%
$ 3.1k
Elizabeta Nemeth
Member of Scientific Advisory Board8.5yrsno datano data
Craig Johnson
Independent Director8.8yrsUS$180.86k0.048%
$ 74.6k
Robert Rosen
Independent Director8.1yrsUS$165.86k0%
$ 0
Paul Adams
Member of Advisory Board7.3yrsno datano data
Victor Gordeuk
Member of Advisory Board7.3yrsno datano data
Ashutosh Lal
Member of Advisory Board7.3yrsno datano data
Gordon McLaren
Member of Advisory Board7.3yrsno datano data
7.7yrs
Average Tenure
57yo
Average Age

Experienced Board: LJPC's board of directors are considered experienced (7.7 years average tenure).


Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2022/08/22 12:32
End of Day Share Price 2022/08/19 00:00
Earnings2022/06/30
Annual Earnings2021/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

La Jolla Pharmaceutical Company is covered by 11 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Keay NakaeChardan Capital Markets, LLC
Reni BenjaminH.C. Wainwright & Co.
Eun Kyung YangJefferies LLC